Does State Medicaid Cover Vardenafil (Levitra/Staxyn)?

The Federal Baseline: Why Medicaid Does Not Guarantee ED Drug Coverage

Federal Medicaid law does not require states to cover drugs used primarily for erectile dysfunction. The Deficit Reduction Act of 2005 explicitly permits states to exclude coverage for agents prescribed for sexual or erectile dysfunction unless those agents are medically necessary for a non-ED condition [1]. That statutory carve-out gives each state broad latitude to set its own policy, which is why coverage for vardenafil ranges from open formulary access in a handful of states to a flat exclusion in others.

What the Federal Exclusion Actually Means

The exclusion does not prohibit states from covering vardenafil. It simply removes the federal requirement. States that choose to cover PDE5 inhibitors must do so with state funds for the ED-specific indication, since federal matching dollars cannot be used for that purpose under 42 C.F.R. § 441.29 [2]. A prescriber documenting a non-ED diagnosis (such as pulmonary arterial hypertension, where sildenafil is labeled but vardenafil is not) would face a different coverage analysis, though off-label Medicaid reimbursement carries its own restrictions.

How States Respond to the Exclusion

Roughly half of state Medicaid programs exclude PDE5 inhibitors entirely for erectile dysfunction. The remaining states may cover generic vardenafil on a restricted formulary tier or under prior authorization. State Medicaid managed care organizations (MCOs) add another layer: even when a state fee-for-service program covers vardenafil, an individual MCO plan operating in that state may apply a different formulary [3].

Checking your specific plan's formulary at point-of-care is the only reliable method. The state Medicaid agency website, the member services phone number on your Medicaid card, and your pharmacist's real-time claims adjudication all provide faster answers than any third-party coverage database.

How Prior Authorization for Vardenafil Works in Medicaid

Prior authorization (PA) is the most common access barrier for vardenafil in states that do cover it. PA criteria differ by state and, within states, by managed care plan, but several requirements appear frequently enough to treat as a general pattern [4].

Typical PA Criteria Medicaid Plans Apply

Most PA forms for vardenafil ask the prescriber to confirm:

• A diagnosis of erectile dysfunction documented in the medical record
• Failure or contraindication to at least one other PDE5 inhibitor, most commonly sildenafil (generic Viagra), which is the lowest-cost agent in the class
• Absence of contraindications such as concurrent nitrate use, which is an absolute contraindication per the FDA prescribing information for vardenafil [5]
• Prescriber attestation that the drug is not being prescribed for a federally excluded indication

Some states add a quantity limit, typically four tablets per 30-day supply, consistent with the approved dosing frequency of once per day as needed.

Step Therapy: Sildenafil Before Vardenafil

Step therapy requiring a trial of sildenafil before vardenafil is standard in states that cover both agents. Sildenafil became generic in 2017 and carries a cash-pay price well below $1 per tablet at major pharmacy chains. The clinical rationale is straightforward: the three oral PDE5 inhibitors approved by the FDA for ED (sildenafil, tadalafil, vardenafil) share a common mechanism of action by inhibiting PDE5, increasing cyclic GMP, and relaxing corporal smooth muscle [6]. Response rates are broadly similar across the class.

Porst et al. (2003, N=580) demonstrated that vardenafil 10 mg and 20 mg produced significantly improved erections compared to placebo across a range of ED severities, with 71% to 75% of intercourse attempts successful in the treated groups versus 49% in the placebo group [7]. That efficacy is real, but it does not differentiate vardenafil from sildenafil on a population level in a way that most Medicaid plans accept as justification for bypassing step therapy.

A prescriber can overcome step therapy when there is a documented clinical reason a patient cannot use sildenafil, such as a drug interaction, a tolerability issue like severe flushing or visual disturbance, or a formulation preference in a patient with swallowing difficulty who qualifies for the Staxyn orally disintegrating tablet.

Quantity Limits and Refill Restrictions

Even with an approved PA, most Medicaid plans impose a quantity limit of four to six units per 30-day fill. Some plans require a new PA every 12 months. Refill-too-soon edits at the pharmacy level are common and may require a manual override from the plan.

What to Do When Medicaid Denies Vardenafil

A denial is not necessarily final. Federal Medicaid regulations guarantee enrollees the right to appeal coverage decisions through a structured process [8].

Step 1: Request a Detailed Denial Notice

The plan must issue a written Notice of Action (NOA) explaining the specific reason for the denial. Vague language like "not medically necessary" is insufficient under federal standards. If the NOA does not cite the specific formulary exclusion or PA criterion that was not met, contact member services and request a complete written explanation before proceeding.

Step 2: Internal Plan Appeal

File an internal appeal within the plan's stated deadline, which is typically 60 days from the NOA date. The appeal must include:

• A letter of medical necessity from the prescribing clinician
• Documentation of any prior PDE5 inhibitor trials and outcomes
• Relevant medical records supporting the diagnosis
• Any published clinical data the prescriber considers relevant to the specific patient case

Porst et al. (2003) remains the most frequently cited primary efficacy trial for vardenafil and may support medical necessity letters when the prescriber argues that vardenafil's pharmacokinetic profile (half-life of approximately 4 to 5 hours, faster onset than tadalafil) is clinically important for a specific patient [7].

Step 3: State Fair Hearing

If the internal appeal fails, enrollees have the right to a state fair hearing before an impartial hearing officer. This right is guaranteed by 42 C.F.R. § 431.200 et seq. [8]. The request must be filed within the timeframe specified on the denial notice, which ranges from 90 to 120 days in most states. At the hearing, the patient and prescriber can present clinical evidence directly. Hearing officers are not bound by the plan's formulary policies if the plan's denial violates state or federal coverage requirements.

Step 4: External Independent Medical Review

Many states also offer an external independent medical review as an alternative or parallel track to the fair hearing. An independent physician, unaffiliated with the plan, reviews the case and renders a binding decision in most state programs. Ask the plan's member services department whether your state offers this option and whether it runs concurrently with or instead of the fair hearing.

Formulary Tiers and Cost Sharing for Vardenafil on Medicaid

When vardenafil is covered, its formulary placement determines what you pay at the pharmacy counter. Medicaid cost sharing is federally capped at nominal amounts for most beneficiaries, but the tier still matters because non-preferred tiers may carry higher copayments or trigger additional PA requirements [9].

Generic Vardenafil vs. Brand Levitra and Staxyn

Generic vardenafil tablets entered the U.S. Market in 2018 after the expiration of the Bayer patent. Brand-name Levitra and the orally disintegrating Staxyn formulation remain available but are priced substantially higher. Most Medicaid formularies that cover vardenafil at all will cover only the generic tablet, not the brand or the ODT formulation, unless the prescriber documents a specific medical necessity for the brand or ODT [10].

The FDA requires generic vardenafil to demonstrate bioequivalence to Levitra, defined as a 90% confidence interval for the ratio of area under the curve (AUC) falling within 80% to 125% of the reference product [11]. For the vast majority of patients, generic and brand are therapeutically interchangeable.

What Patients Actually Pay

For Medicaid beneficiaries with ED drug coverage and no cost-sharing exemption, copayments typically range from $1 to $4 per prescription. That is substantially less than the cash-pay average of approximately $120 per month for generic vardenafil. Even GoodRx and similar discount programs do not usually reduce the cash price below $80 to $100 for a supply of 30 tablets.

Patients who cannot obtain Medicaid coverage for vardenafil have three realistic options: pay cash with a discount program, ask the prescriber about sildenafil (often available for under $0.50 per tablet on cash pay), or explore whether tadalafil daily dosing (5 mg) meets clinical needs at a lower out-of-pocket cost.

The Manufacturer Savings Card Question

Manufacturer copay cards for Levitra and Staxyn, offered by Bayer at various times, cannot be used by patients who have active Medicaid coverage. Federal anti-kickback statutes prohibit using manufacturer assistance programs to reduce out-of-pocket costs for federal health program beneficiaries, including Medicaid [12]. Pharmacies are also contractually prohibited from billing Medicaid while simultaneously applying a manufacturer coupon to the same claim.

This restriction applies regardless of state. A patient who is Medicaid-eligible cannot legally use a Bayer savings card for brand Levitra or Staxyn while Medicaid is their primary insurer. Patients who have lapsed coverage or are in a spend-down period may have a different eligibility picture, but verifying that with a healthcare attorney or benefits counselor before proceeding is advisable.

Vardenafil for Conditions Other Than Erectile Dysfunction

Sildenafil (Revatio) is FDA-approved for pulmonary arterial hypertension (PAH). Vardenafil carries no FDA approval for PAH, though some investigator-initiated research has explored the class effect [13]. Medicaid coverage for an off-label PAH indication is unlikely without extraordinary documentation. Prescribers should not attempt to code a PAH diagnosis to obtain vardenafil coverage for ED; doing so constitutes fraud under 18 U.S.C. § 1347 and exposes both prescriber and patient to federal liability.

For ED caused by a comorbid condition such as diabetes-related neuropathy or hypogonadism, the underlying condition may itself carry Medicaid coverage implications for related treatments. A urologist or endocrinologist can often document a more specific medical necessity rationale than a primary care letter alone.

State-by-State Patterns: What Medicaid Programs Typically Do

No single federal database publishes real-time formulary data for all 50 state Medicaid programs plus the District of Columbia. The following patterns reflect publicly available preferred drug list (PDL) documents and Medicaid managed care formulary filings reviewed as of mid-2025. Always verify with your plan directly.

States More Likely to Cover Generic Vardenafil (With PA)

States with larger Medicaid managed care markets and active pharmacy benefit managers tend to cover generic vardenafil under PA with step therapy. These often include states in the Northeast and Upper Midwest that have expanded Medicaid under the ACA and have formulary review processes that apply cost-effectiveness criteria across the PDE5 inhibitor class. The Centers for Medicare and Medicaid Services (CMS) publishes Medicaid state plan amendments and managed care contract summaries that can help identify these states [14].

States That Exclude PDE5 Inhibitors Entirely

A significant number of states apply a blanket exclusion for drugs prescribed for sexual dysfunction, citing the Deficit Reduction Act authority. In these states, no PA pathway exists for ED indications, and appeals on formulary grounds will not succeed unless the prescriber documents a covered medical condition driving the prescription.

Checking Your State's PDL

Every state Medicaid program must maintain a publicly accessible preferred drug list. CMS requires states to post these documents and update them at regular intervals [15]. Search your state Medicaid agency website for "preferred drug list" or "formulary" to find the most current version. Look under the genitourinary or cardiovascular drug category, or search the document for "vardenafil" or "PDE5."

Dosing Reference for Prescribers Completing PA Forms

The FDA-approved dosing range for vardenafil is 5 mg to 20 mg taken orally approximately 60 minutes before sexual activity, no more than once daily [5]. The starting dose is typically 10 mg. Dose adjustments are required for patients taking moderate CYP3A4 inhibitors (maximum 5 mg per 24 hours) and for patients with moderate hepatic impairment (Child-Pugh B, maximum 5 mg). The drug is contraindicated with nitrates and with potent CYP3A4 inhibitors such as ketoconazole and ritonavir [5].

Prescribers completing PA forms should document the specific dose prescribed, the frequency, any dose adjustments made for drug interactions or organ impairment, and the clinical rationale for vardenafil rather than sildenafil. Plans reviewing PA requests look for exactly these details; vague forms are denied at higher rates [16].

Comparing PDE5 Inhibitors on Medicaid Formularies

Understanding where vardenafil sits relative to sildenafil and tadalafil on Medicaid formularies can help a prescriber and patient choose the most accessible and cost-effective option.

Sildenafil: The Default First-Line Agent on Most Formularies

Generic sildenafil (Viagra equivalent) is the lowest-cost PDE5 inhibitor and appears on virtually every Medicaid formulary that covers ED drugs at all. Cash-pay prices at discount pharmacies commonly run below $15 for 10 tablets of 100 mg. For many Medicaid beneficiaries, sildenafil is the practical answer even when vardenafil is the preferred agent clinically.

Tadalafil: The Once-Daily Option

Generic tadalafil (Cialis equivalent) is available as a 5 mg daily formulation for men who prefer continuous coverage rather than as-needed dosing. Some Medicaid formularies prefer tadalafil over vardenafil on cost grounds. Tadalafil's half-life of approximately 17.5 hours allows more flexible timing than vardenafil's 4 to 5 hour half-life [17].

Avanafil: Least Likely to Be Covered

Avanafil (Stendra) lacks a generic formulation as of mid-2025 and carries the highest list price among oral PDE5 inhibitors. Medicaid coverage is rare. Prescribers should not expect Medicaid plans to approve avanafil before exhausting the generic options.

Clinical Takeaway for Prescribers and Patients

A denied Medicaid claim for vardenafil is a starting point, not a final answer. Document the clinical reason vardenafil specifically is needed, complete a detailed PA request, and if denied, file the internal appeal with supporting literature before proceeding to a state fair hearing. The FDA label for vardenafil specifies a starting dose of 10 mg taken orally 60 minutes before sexual activity [5], and that specific clinical instruction belongs on every PA form and appeal letter you submit.